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Introduction: Wilms tumour (WT) is an embryonal kidney neoplasia in which the 
causative mutations are largely unknown. However, approximately one third of patients 
display somatic mutations in WT1, CTNNB1, TP53 and/or WTX genes, prompting the 
design of molecular tests to determine the mutational profile of each patient. In this 
work we describe a novel molecular assay based on next-generation sequencing 
(NGS) technology which we used to identify mutations in 36 Portuguese WT patients. 
 
Methods: Design Studio (Illumina) was used to create a sequencing panel of 83 PCR 
amplicons covering 12.306 bases of exonic sequences of WT1, CTNNB1, TP53 and 
WTX genes. Amplicons were prepared from tumour and matched peripheral blood 
DNA samples (n=73) using a TruSeq Custom Amplicon kit (Illumina). Libraries were 
sequenced on a MiSeq instrument using paired-end 250 bp reads. Sequence reads 
were aligned to hg19 human genome reference sequence using MiSeq Reporter 
software (Illumina). Variants were annotated using publicly available databases. 
 
Results: Data analysis of the constitutional DNA of WT patients showed the existence 
of 31 germline variants, including 9 variants not described in the human dbSNP 
database. Comparison of matched tumour samples revealed the presence of 14 
putative mutations in 12 patients. The mutations included WT1 (n=3), CTNNB1 (n=4), 
WTX (n=5) and TP53 (n=2). In one patient, concomitant WT1 and CTNNB1 mutations 
were found. Comparison of results with previous Sanger sequencing data for WT1 and 
CTNNB1 in the same samples confirmed 5 out of 7 mutations detected by NGS in 
which the mutated allele frequency was above 20%.  
 
Discussion: We conclude that gene panel sequencing is a fast and sensitive molecular 
assay for identification of recurrent somatic mutations in WT. However, because two 
thirds of patients lack known mutations, other NGS-based approaches such as exome 
sequencing may be fruitful to identify novel mutations in WT. 
